Abstract:ObjectiveTo investigate the value of combined measurement of alpha-fetoprotein (AFP) and AFP-L3% in the diagnosis of hepatocellular carcinoma (HCC). MethodsA retrospective analysis was performed for serological parameters and clinical data of 1208 patients with chronic hepatitis, 1967 patients with liver cirrhosis, and 1569 patients with primary HCC who attended The Fifth Medical Center of Chinese PLA General Hospital from January 2010 to December 2017. The distribution of serum AFP and AFP-L3% was analyzed, and AFP alone, AFP-L3% alone, and AFP combined with AFP-L3% were compared in terms of sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). The correlation of AFP with AFP-L3 level and AFP-L3% was also analyzed. A one-way analysis of variance or the Kruskal-Wallis H test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. The Spearman rank correlation test was used for correlation analysis of continuous data, the Delong test was used for comparison of AUC, and logistic regression was used to establish the model of AFP combined with AFP-L3% for the diagnosis of HCC. ResultsThe HCC group had significantly higher serum levels of AFP and AFP-L3 than the liver cirrhosis group and the chronic hepatitis group (H=1107.3 and 1076.9, both P＜0.01). The HCC group had a significantly higher positive rate of AFP-L3% than the liver cirrhosis group and the chronic hepatitis group (30.9% vs 3.0%/2.8%, P＜0.01). The HCC group had a significantly higher level of AFP-L3 than the liver cirrhosis group and the chronic hepatitis group （3.3(0-13.4)% vs 0/0, H=1034.1, P＜001）. The correlation analysis showed that serum AFP was significantly correlated with AFP-L3 level (r=0.91, P＜0.01), and there was no correlation between AFP-L3% and AFP (r=0.04, P＞0.05). With specificity remaining the same, AFP combined with AFP-L3% had a significantly higher sensitivity in the diagnosis of HCC than AFP alone (26.6% vs 18.4%, P＜0.01) or AFP-L3% alone (36.6% vs 30.9%, P＜0.01). The subgroup analysis showed that for the samples with AFP ≥10 μg/L, AFP combined with AFP-L3% had a significantly higher AUC in the diagnosis of HCC than AFP alone (0.745 vs 0.701, P＜0.01); for the tumor with a diameter of ＞2 cm or hepatitis B-related liver cancer, AFP combined with AFP-L3% had a significantly higher sensitivity than AFP alone (27.6% vs 180%/27.7% vs 19.1%, both P＜0.01) or AFP-L3% alone (37.0% vs 30.3%/36.9% vs 31.8%, both P＜0.01). For the group with a tumor diameter of ≤2 cm and the group without hepatitis B-related liver cancer, there was no significant difference in sensitivity between AFP combined with AFP-L3% and AFP or AFP-L3% alone in the diagnosis of HCC (all P＞0.05). ConclusionAFP combined with AFP-L3% can significantly improve the sensitivity of HCC diagnosis and has a good clinical value in the diagnosis of hepatitis B-related liver cancer and liver cancer with a tumor diameter of ＞2 cm.

Dual-label time-resolved immunofluorometric assay of serum AFP and AFP-IgM in patients with hepatocellular carcinoma

Simultaneous Determination of Alpha-Fetoprotein Immune Complexes and Alpha-Fetoprotein Concentration in Hepatocellular Carcinoma Using Dual-Label Time-Resolved Immunofluorometric Assays.

Combined determination of serum DCP, GPC3 and HSP70 in diagnosis of AFP-negative primary liver carcinoma

Evaluation of hepatocellular carcinoma by combined detection of serum AFP-IgM complex and liver function

Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.

Clinical Application of Determining Serum AFP-IgM Complexes for Diagnosis of Small Hepatocellular Carcinoma.

Intramolecular Fluorescence Resonance Energy Transfer Strategy for Accurate Detection of AFP-L3% and Improved Diagnosis of Hepatocellular Carcinoma

Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma.

Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases

Detection of the Diagnosis about Primary Hepatocellular Carcinoma with the AFP-IgM Immune Complexes in Serum

Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma.

Roles of combined detection of AFP, GGT-II and sICAM-1 in the diagnosis of hepatocellular carcinoma

Expression of AFP-IgM Immune Complexes in Hepatocellular Carcinoma and Its Clinical Significance

Quantitative Analysis of Hepatoma-Specific Α-Fetoprotein (HS-AFP) by a New Mini-Column Affinity Chromatography and Its Clinical Value in Diagnosis of Hepatocellular Carcinoma

Value of combined measurement of alpha-fetoprotein and alpha-fetoprotein L3％in the diagnosis of hepatocellular carcinoma

Application of ROC Curve in the Evaluation of the Diagnostic Value of AFP Determined by TRFIA and RIA in HCC

Diagnostic Value of Multiple Serum Tumor Markers for Hepatocellular Carcinoma

[Detection of Alpha-Fetoprotein-l3 Using Agglutinin-Coupled Spin Column to Be Used in Diagnosis of Hepatocellular Carcinoma].

Mass Spectrometric Assay of Alpha-Fetoprotein Isoforms for Accurate Serological Evaluation.

Diagnostic value of serum AFP and AFU detection in primary hepatic carcinoma

The Expression and Significance of Serum AFP-IgM Immune Complexes in Hepatocellular Carcinoma